Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13860MR)

This product GTTS-WQ13860MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13860MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8745MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ3451MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AZD8895
GTTS-WQ7634MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GEN1029
GTTS-WQ7781MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GS-5745
GTTS-WQ7631MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GEN1029
GTTS-WQ3412MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aALB03
GTTS-WQ8951MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ2311MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALXN-1210
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW